Log in

Relevant bibliographies by topics / Low molecular weight heparin / Journal articles

To see the other types of publications on this topic, follow the link: Low molecular weight heparin.

Journal articles on the topic 'Low molecular weight heparin'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Low molecular weight heparin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

&NA;. "Heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 1414 (2012): 28–29. http://dx.doi.org/10.2165/00128415-201214140-00091.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Heparin/low-molecular-weight heparins." Reactions Weekly &NA;, no. 1198 (2008): 22. http://dx.doi.org/10.2165/00128415-200811980-00068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 1210 (2008): 18. http://dx.doi.org/10.2165/00128415-200812100-00051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

&NA;. "Heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 1211 (2008): 17–18. http://dx.doi.org/10.2165/00128415-200812110-00053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 1211 (2008): 18. http://dx.doi.org/10.2165/00128415-200812110-00056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 1277 (2009): 23. http://dx.doi.org/10.2165/00128415-200912770-00068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

&NA;. "Heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 1231 (2008): 16–17. http://dx.doi.org/10.2165/00128415-200812310-00049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 989 (2004): 10. http://dx.doi.org/10.2165/00128415-200409890-00030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Mulloy, Barbara, Trevor Barrowcliffe, and Elaine Gray. "Heparin and low-molecular-weight heparin." Thrombosis and Haemostasis 99, no. 11 (2008): 807–18. http://dx.doi.org/10.1160/th08-01-0032.

Full text

Abstract:

SummaryHeparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration. They have been shown to be at least as effective and safe as unfractionated heparin and have replaced the latter in many indications. In this article the chemistry, mechanisms of action, measurement of anticoagulant activities, and clinical status of heparin and LMWH are reviewed.

APA, Harvard, Vancouver, ISO, and other styles

10

Hoppensteadt, Debra, Jeanine M. Walenga, Jawed Fareed, and Rodger L. Bick. "Heparin, low–molecular-weight heparins, and heparin pentasaccharide." Hematology/Oncology Clinics of North America 17, no. 1 (2003): 313–41. http://dx.doi.org/10.1016/s0889-8588(02)00091-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

&NA;. "Heparin/low molecular weight heparins/warfarin." Reactions Weekly &NA;, no. 1321 (2010): 20. http://dx.doi.org/10.2165/00128415-201013210-00061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Hirsh, Jack. "Heparin and low-molecular weight heparins." Coronary Artery Disease 3, no. 11 (1992): 990–1002. http://dx.doi.org/10.1097/00019501-199211000-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

&NA;. "Heparin/low-molecular weight heparin." Reactions Weekly &NA;, no. 1216 (2008): 19. http://dx.doi.org/10.2165/00128415-200812160-00049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Mulloy, B., C. Gee, S. F. Wheeler, R. Wait, E. Gray, and T. W. Barrowcliffe. "Molecular Weight Measurements of Low Molecular Weight Heparins by Gel Permeation Chromatography." Thrombosis and Haemostasis 77, no. 04 (1997): 668–74. http://dx.doi.org/10.1055/s-0038-1656031.

Full text

Abstract:

SummaryThe molecular weight profiles of low molecular weight heparin samples have been measured by high-performance gel permeation chromatography using as calibrant the heparinase-degraded material (90/686) now established as the 1st International Reference Preparation (IRP) Low Molecular Weight Heparin for Molecular Weight Calibration. Use of the calibrant as a broad molecular weight standard is described and a calibration table provided based on data collected over several years in one laboratory.In order to confirm the assignment of degree of polymerisation to resolved oligosaccharide peaks

APA, Harvard, Vancouver, ISO, and other styles

15

Martinez-Salas, José, Richard Mendelssohn, William M. Abraham, Bernard Hsiao, and Tahir Ahmed. "Inhibition of allergic airway responses by inhaled low-molecular-weight heparins: molecular-weight dependence." Journal of Applied Physiology 84, no. 1 (1998): 222–28. http://dx.doi.org/10.1152/jappl.1998.84.1.222.

Full text

Abstract:

Martinez-Salas, José, Richard Mendelssohn, William M. Abraham, Bernard Hsiao, and Tahir Ahmed. Inhibition of allergic airway responses by inhaled low-molecular-weight heparins: molecular-weight dependence. J. Appl. Physiol. 84(1): 222–228, 1998.—Inhaled heparin prevents antigen-induced bronchoconstriction and inhibits anti-immunoglobulin E-mediated mast cell degranulation. We hypothesized that the antiallergic action of heparin may be molecular weight dependent. Therefore, we studied the effects of three different low-molecular-weight fractions of heparin [medium-, low-, and ultralow-molecular

APA, Harvard, Vancouver, ISO, and other styles

16

Barrowcliffe, T. W., A. D. Curtis, E. A. Johnson, and D. P. Thomas. "An International Standard for Low Molecular Weight Heparin." Thrombosis and Haemostasis 60, no. 01 (1988): 001–7. http://dx.doi.org/10.1055/s-0038-1647623.

Full text

Abstract:

SummaryAn international collaborative study has been carried out with the aim of establishing an international standard for low molecular weight (LMW) heparin. Three preparations of LMW heparin were assayed against the International Standard for unfractionated heparin (UFH) by 25 laboratories in 13 countries, using nine different assay methods. The results confirmed previous findings of non-parallel assays, wide interlaboratory variability and differences between methods when LMW heparins are assayed against a UFH standard. Use of one of the LMW heparins as a standard for the other two gave pa

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Danaparoid sodium/heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 1269 (2009): 15–16. http://dx.doi.org/10.2165/00128415-200912690-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Low molecular weight heparins challenge standard heparin." Inpharma Weekly &NA;, no. 805 (1991): 22–23. http://dx.doi.org/10.2165/00128413-199108050-00057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Fareed, Jawed, Walter Jeske, Daniel Fareed, et al. "Are All Low Molecular Weight Heparins Equivalent in the Management of Venous Thromboembolism?" Clinical and Applied Thrombosis/Hemostasis 14, no. 4 (2007): 385–92. http://dx.doi.org/10.1177/1076029608319881.

Full text

Abstract:

Low molecular weight heparins are replacing unfractionated heparin in a number of clinical indications because of their improved subcutaneous bioavailability and more predictable antithrombotic response. Clinical trials have demonstrated that low molecular weight heparins are at least as safe and effective as unfractionated heparin for the initial treatment of venous thromboembolism, and unfractionated heparin and warfarin for primary and secondary thromboprophylaxis. The mechanism behind the antithrombotic action of low molecular weight heparins is not fully understood but is likely to involv

APA, Harvard, Vancouver, ISO, and other styles

20

Chen, Jianle, Yanlei Yu, Jawed Fareed, et al. "Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin." Clinical and Applied Thrombosis/Hemostasis 25 (January 1, 2019): 107602961984070. http://dx.doi.org/10.1177/1076029619840701.

Full text

Abstract:

Heparin and its low-molecular-weight heparin derivatives are widely used clinical anticoagulants. These drugs are critical for the practice of medicine in applications, including kidney dialysis, cardiopulmonary bypass, and in the management of venous thromboembolism. Currently, these drugs are derived from livestock, primarily porcine intestine and less frequently bovine intestine and bovine lung. The worldwide dependence on the pig as a single dominant animal species has made the supply chain for this critical drug quite fragile, leading to the search for other sources of these drugs, includ

APA, Harvard, Vancouver, ISO, and other styles

21

Hirsh, Jack, and Robert Raschke. "Heparin and Low-Molecular-Weight Heparin." Chest 126, no. 3 (2004): 188S—203S. http://dx.doi.org/10.1378/chest.126.3_suppl.188s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Hirsh, Jack, Theodore E. Warkentin, Robert Raschke, Christopher Granger, E. Magnus Ohman, and James E. Dalen. "Heparin and Low-Molecular-Weight Heparin." Chest 114, no. 5 (1998): 489S—510S. http://dx.doi.org/10.1378/chest.114.5_supplement.489s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Low molecular weight heparin." Reactions Weekly &NA;, no. 1148 (2007): 25. http://dx.doi.org/10.2165/00128415-200711480-00081.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Whang, Peter G., and Jay R. Lieberman. "Low-Molecular-Weight Heparin." Journal of the American Academy of Orthopaedic Surgeons 10, no. 5 (2002): 299–302. http://dx.doi.org/10.5435/00124635-200209000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Low-molecular-weight heparin." Reactions Weekly &NA;, no. 683 (1998): 10. http://dx.doi.org/10.2165/00128415-199806830-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Low molecular weight heparin." Reactions Weekly &NA;, no. 378 (1991): 6. http://dx.doi.org/10.2165/00128415-199103780-00028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Low molecular weight heparin." Reactions Weekly &NA;, no. 417 (1992): 10. http://dx.doi.org/10.2165/00128415-199204170-00038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Low molecular weight heparin." Reactions Weekly &NA;, no. 341 (1991): 7. http://dx.doi.org/10.2165/00128415-199103410-00040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

&NA;. "Low molecular weight heparin." Reactions Weekly &NA;, no. 357 (1991): 8. http://dx.doi.org/10.2165/00128415-199103570-00035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Hirsh, J., and MN Levine. "Low molecular weight heparin." Blood 79, no. 1 (1992): 1–17. http://dx.doi.org/10.1182/blood.v79.1.1.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Hirsh, J., and MN Levine. "Low molecular weight heparin." Blood 79, no. 1 (1992): 1–17. http://dx.doi.org/10.1182/blood.v79.1.1.bloodjournal7911.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Hirsh, Jack. "Low Molecular Weight Heparin." Thrombosis and Haemostasis 70, no. 01 (1993): 204–7. http://dx.doi.org/10.1055/s-0038-1646191.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Hirsh, Jack. "Low-Molecular-Weight Heparin." Circulation 98, no. 15 (1998): 1575–82. http://dx.doi.org/10.1161/01.cir.98.15.1575.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Heit, John A. "Low-Molecular-Weight Heparin." Regional Anesthesia and Pain Medicine 23, Sup 2 (1998): 135–39. http://dx.doi.org/10.1097/00115550-199823062-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Routledge, P. A., and R. R. West. "Low molecular weight heparin." BMJ 305, no. 6859 (1992): 906. http://dx.doi.org/10.1136/bmj.305.6859.906.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Horlocker, Terese T., and John A. Heit. "Low Molecular Weight Heparin." Anesthesia & Analgesia 85, no. 4 (1997): 874–85. http://dx.doi.org/10.1097/00000539-199710000-00031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Hunt, B. J. "Low Molecular Weight Heparin." Blood Coagulation & Fibrinolysis 3, no. 5 (1992): 683. http://dx.doi.org/10.1097/00001721-199210000-00030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Schmitt, Y., and H. Schneider. "Low molecular weight heparin." Blood Coagulation & Fibrinolysis 7, no. 3 (1996): 385. http://dx.doi.org/10.1097/00001721-199604000-00051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Horlocker, Terese T., and John A. Heit. "Low Molecular Weight Heparin." Anesthesia & Analgesia 85, no. 4 (1997): 874–85. http://dx.doi.org/10.1213/00000539-199710000-00031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Wolf, Helmut. "Low-molecular-weight heparin." Medical Clinics of North America 78, no. 3 (1994): 733–43. http://dx.doi.org/10.1016/s0025-7125(16)30155-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Nunnelee, Janice D. "Low-molecular-weight heparin." Journal of Vascular Nursing 15, no. 3 (1997): 94–96. http://dx.doi.org/10.1016/s1062-0303(97)90057-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Vanpee, Dominique, Jean-Bernard Gillet, and Christian Swine. "Low Molecular Weight Heparin." Annals of Emergency Medicine 36, no. 3 (2000): 277. http://dx.doi.org/10.1067/mem.2000.109264.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Salzman, Edwin W. "Low-Molecular-Weight Heparin." New England Journal of Medicine 315, no. 15 (1986): 957–59. http://dx.doi.org/10.1056/nejm198610093151509.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Gough, S. "Low molecular weight heparin." BMJ 303, no. 6805 (1991): 784. http://dx.doi.org/10.1136/bmj.303.6805.784-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Brack, M. J. "Low molecular weight heparin." International Journal of Cardiology 38, no. 2 (1993): 207–8. http://dx.doi.org/10.1016/0167-5273(93)90193-k.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Barrowcliffe, T. W., A. D. Curtis, T. P. Tomlinson, A. R. Hubbard, E. A. Johnson, and D. P. Thomas. "Standardization of Low Molecular Weight Heparins : A Collaborative Study." Thrombosis and Haemostasis 54, no. 03 (1985): 675–79. http://dx.doi.org/10.1055/s-0038-1660095.

Full text

Abstract:

SummaryA collaborative study was carried out, in which eight laboratories each assayed eight low molecular weight (LMW) heparins against the International Standard (IS) for heparin. APTT assays and three types of anti-Xa method were used. The results of this study showed that:1. LMW heparins cannot be validly assayed against the IS by APTT or anti-Xa methods.2. Potencies of LMW heparins vs. the IS differed considerably between the four types of assay method used and also between different laboratories using the same type of method.3. Adoption of a single LMW heparin standard would improve vali

APA, Harvard, Vancouver, ISO, and other styles

47

Shaughnessy, SG, E. Young, P. Deschamps, and J. Hirsh. "The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria." Blood 86, no. 4 (1995): 1368–73. http://dx.doi.org/10.1182/blood.v86.4.1368.bloodjournal8641368.

Full text

Abstract:

Osteoporosis is a well-recognized complication of long-term heparin use. However, the mechanisms by which heparin can influence bone metabolism are unclear. We report here that unfractionated heparin stimulates the process of bone resorption and that the low molecular weight heparins (LMWHs), enoxaparin, fragmin, logiparin, and ardeparin produce significantly less calcium loss than unfractionated heparin. To assess calcium loss from bone, we quantified the release of 45Ca into the culture medium of fetal rat calvaria. 45Ca release was increased in a dose-dependent manner by the addition of eit

APA, Harvard, Vancouver, ISO, and other styles

48

Mammen, Eberhard F. "Low Molecular Weight Heparins and Heparin-Induced Thrombocytopenia." Clinical and Applied Thrombosis/Hemostasis 5, no. 1_suppl (1999): S72—S75. http://dx.doi.org/10.1177/10760296990050s113.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Ambrosioni, E., and E. Strocchi. "Pharmacokinetics of Heparin and Low Molecular Weight Heparins." Pathophysiology of Haemostasis and Thrombosis 20, no. 1 (1990): 94–97. http://dx.doi.org/10.1159/000216165.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Gurfinkel, Enrique P., Jose Santopinto, Gerardo E. Bozovich, Alberto Quispe, Alejandra Strinna, and Branco Mautner. "Low-molecular-weight heparin alone versus a combination of unfractionated heparin and low-molecular-weight heparin." American Heart Journal 140, no. 1 (2000): 13A—18A. http://dx.doi.org/10.1067/mhj.2000.106643.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!